You just read:

SELLAS™ Life Sciences Announces Positive Interim Phase II Results from its WT1 Immunotherapeutic Anti-cancer Treatment in Multiple Myeloma Patients

News provided by

SELLAS Life Sciences Group

Oct 13, 2016, 09:30 ET